Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market
17 mai 2023 08h15 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
Optimi Health Granted Natural Health Product Site Licence By Health Canada
10 mai 2023 08h45 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...
Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical Research and Development
04 mai 2023 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 04, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), today announced that it has entered into a...
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
01 mars 2023 07h30 HE
|
Optimi Health Corp.
Highlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using...
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists
07 févr. 2023 10h31 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
06 févr. 2023 08h30 HE
|
Optimi Health Corp.
The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under...
Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements
17 janv. 2023 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer...
Optimi Health Announces Re-Appointments to Board of Directors
10 janv. 2023 16h15 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that Mr. Bryan Safarik,...
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
06 oct. 2022 12h51 HE
|
Optimi Health Corp.
Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable...
Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History
08 sept. 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed...